ARTICLE | Clinical News
Bempedoic acid regulatory update
October 5, 2015 7:00 AM UTC
FDA encouraged Esperion to begin a cardiovascular outcomes trial (CVOT) for ETC-1002 to treat hypercholesterolemia as concerns about the benefit risk/assessment “could necessitate” a completed CVOT be...